Polaryx Therapeutics, Inc. PLYX Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Polaryx Therapeutics, Inc. 's total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's total cash, cash equivalents, and restricted cash (inclusive)?
- Polaryx Therapeutics, Inc. (PLYX) reported total cash, cash equivalents, and restricted cash (inclusive) of 514,300,000% in Q4 2025.
- What is the long-term trend for Polaryx Therapeutics, Inc. 's total cash, cash equivalents, and restricted cash (inclusive)?
- Over 2 years (2023 to 2025), Polaryx Therapeutics, Inc. 's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 4971.0% compound annual growth rate (CAGR), from 200,000% to 514,300,000%.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- The total amount of cash, highly liquid investments, and restricted cash held by the company. This represents the immediate liquidity available to fund operations, research, and development activities.